MULTIPLE MYELOMA KNOWLEDGE CENTER

How is Ninlaro administered?

Ninlaro® (ixazomib, Takeda Oncology) is an oral medication. It is available as 4 mg, 3 mg, and 2.3 mg capsules.

The recommended starting dose of Ninlaro is 4 mg orally once a week on days 1, 8, and 15 of each 4-week cycle along with Revlimid® (lenalidomide, Celgene) and dexamethasone.

  • Patients with moderately or severely reduced liver function (hepatic impairment) will typically receive a lower (3 mg) starting dose of Ninlaro.
  • Patients with severely reduced kidney function (renal impairment) and patients receiving dialysis will also typically receive a 3-mg starting dose of Ninlaro.

Revlimid is taken orally at 25 mg on days 1 to 21 of each cycle and dexamethasone is taken orally at 40 mg on days 1, 8, 15, and 22 of each cycle. In addition, a blood thinner such as aspirin is typically taken along with Revlimid-dexamethasone to reduce the chance of developing a blood clot.

Patients receive Ninlaro, Revlimid, and dexamethasone until their disease progresses or they experience unacceptable side effects.

Ninlaro should be taken with water once a week on the same day and at approximately the same time. It should be taken at least 1 hour before or at least 2 hours after eating, separately from dexamethasone, which should be taken with food.

If you are late in taking a dose of Ninlaro or you miss a dose, take this dose if your next scheduled dose is at least 72 hours (3 days) away. Do not take this dose if your next dose is scheduled within 3 days. Do not take a double dose to make up for a missed dose.

If you vomit after taking Ninlaro, do not take another dose. Wait until your next scheduled dose to resume Ninlaro.